CRISPR/Cas9-based transcriptional activation (CRISPRa) and repression (CRISPRi) provide a powerful new set of tools for studying gene function in vivo. A major advantage of these systems is that any gene-of-interest can be targeted using a ~20bp guide RNA, making this approach versatile and scalable. However, several different dCas9-fusions and sgRNA design rules have recently been published, and the most effective approaches have not been defined. In this study, we directly compare different dCas9-fusion proteins for both CRISPRa and CRISPRi in vivo, and identify highly effective approaches for each. We also present a growing collection of publically available Drosophila stocks for activating and repressing target genes in various tissues. Together, these studies lay a foundation for our ongoing effort to generate a genome-wide resource for CRISPRa and CRISPRi for the Drosophila community.